Good points, Celtics.It's always good to see you keeping such a firm grasp on this little stock. Ah, but then, maybe it will be looking a lot less "little" or "micro" by the end of this year. To see the financials looking so positive, the net results turning to cash-flow positive, with Scrips moving from the stage of exploring new types of market opportunity (first and foremost compound pharmacies) to a phase of exploding revenue increases – that is, in fact, a rare situation to be in.